Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date † | December 17, 2003 | ||||
Last Updated Date | October 4, 2007 | ||||
Start Date † | November 2003 | ||||
Current Primary Outcome Measures † |
To determine the safety and tolerability of SPP200 in patients undergoing chronic haemodialysis via an arteriovenous graft. | ||||
Original Primary Outcome Measures † | Same as current | ||||
Change History | Complete list of historical versions of study NCT00074620 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures † |
To determine the efficacy of PEG-hirudin compared to unfractionated heparin (UFH) on the frequency of vascular graft occlusions and on time to first graft occlusions. | ||||
Original Secondary Outcome Measures † | Same as current | ||||
Descriptive Information | |||||
Brief Title † | A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis | ||||
Official Title † | A Randomised, Multicenter, Open-Label, Parallel Group Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Unfractionated Heparin as Anticoagulant Treatment in Patients Undergoing Haemodialysis Via an Arteriovenous Graft | ||||
Brief Summary | The study will look at the safety profile (unwanted effects) of the long-lasting anticoagulant PEG-hirudin (SPP200) and compare these unwanted effects to those of unfractionated heparin, commonly used in haemodialysis to avoid clotting of the graft and of the haemodialysis machine. |
||||
Detailed Description | |||||
Study Phase | Phase II | ||||
Study Type † | Interventional | ||||
Study Design † | Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety Study | ||||
Condition † |
|
||||
Intervention † | Drug: PEG-hirudin | ||||
Study Arms / Comparison Groups | |||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status † | Completed | ||||
Enrollment † | 260 | ||||
Completion Date | January 2006 | ||||
Primary Completion Date | |||||
Eligibility Criteria † |
|
||||
Gender | Both | ||||
Ages | 21 Years to 75 Years | ||||
Accepts Healthy Volunteers | No | ||||
Contacts †† | |||||
Location Countries † | United States | ||||
Expanded Access Status | |||||
Administrative Information | |||||
NCT ID † | NCT00074620 | ||||
Responsible Party | |||||
Secondary IDs †† | |||||
Study Sponsor † | Speedel Pharma Ltd. | ||||
Collaborators †† | Quintiles | ||||
Investigators † |
|
||||
Information Provided By | Speedel Pharma Ltd. | ||||
Verification Date | October 2007 | ||||
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |